Nevro yesterday announced that the FDA has granted approval for a study evaluating its high-frequency spinal cord stimulation system for the treatment of chronic pain. The device company’s Senza ...

HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real ...

REDWOOD CITY, Calif., Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

Data Published in Journal of Neurosurgery: Spine Highlight Lasting Pain Relief, Enhanced Function, Quality of Life, and Reduced Opioid Dependency with High-Frequency SCS Therapy The published 24-month ...

Publications Show Reductions in Hospital Resource Utilization Associated with 10 kHz Therapy Spinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Nonsurgical Refractory Back ...

Nevro is bringing artificial intelligence to its spinal cord stimulation solutions. The Redwood City, CA-based company said it won FDA approval for the HFX iQ with HFX AdaptivAI - a responsive, ...

Nevro today announced that it received two patents for its Senza High-Frequency Spinal Cord Stimulation System, a device aimed at patients with chronic pain. The first patent concerns the device’s ...

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic ...

Nevro Corp. recently received CE Mark Certification in Europe for its HFX iQ spinal cord stimulation (SCS) system. The company can now market HFX iQ in all countries that recognize this certification.

Nevro is looking at strategic options after citing heavy competition from larger players in the spinal cord stimulation market. The measure comes several months after Nevro announced it would cut ...

New 18-month data for a 10-kHz implanted spinal cord stimulation device (Nevro) shows continued relief of painful diabetic neuropathy symptoms in patients refractory to conventional medical therapy.

Globus Medial completed its acquisition of Nevero, a spinal cord stimulator company, according to an April 3 news release. The acquisition expands Globus Medical’s reach in the musculoskeletal market ...